Middle East African Journal of Ophthalmology

ORIGINAL ARTICLE
Year
: 2021  |  Volume : 28  |  Issue : 2  |  Page : 98--103

Bromfenac 0.09% for the treatment of macular edema secondary to noninfectious uveitis


Joanna S Saade1, Rachid Istambouli1, Marwan AbdulAal2, Rafic Antonios1, Rola N Hamam1 
1 Department of Ophthalmology, American University of Beirut Medical Center, Beirut, Lebanon
2 Department of Ophthalmology, Case Western Reserve University, Cleveland, Ohio, USA

Correspondence Address:
Dr. Rola N Hamam
American University of Beirut Medical Center, Riad El Solh 11072020, P. O. Box: 11-0236/D41, Beirut
Lebanon

PURPOSE: The topical nonsteroidal anti-inflammatory drug bromfenac 0.09% has a potential benefit in uveitic macular edema (UME) with a safe side effect profile. The aim of the study is to assess the efficacy of bromfenac sodium solution in the treatment of UME. METHODS: The charts of 10 patients with macular edema due to noninfectious uveitis treated with bromfenac 0.09% were reviewed retrospectively. The main outcomes studied were the best-corrected visual acuity (BCVA) and the central retinal thickness (CRT) compared 4 months before bromfenac initiation, at the time of its initiation, and 4 months later. RESULTS: Twelve eyes of 10 patients were included. BCVA and CRT were unchanged 4 months befoew bromfenac compared to the time of bromfenac initiation (P = 1.0 and P = 0.2, respectively). There were a significant improvement in BCVA after 4 months of bromfenac treatment (P = 0.043) and a significant decrease in CRT (P = 0.002). Subretinal fluid resolved completely in 8/9 eyes, and 4/9 eyes had a complete resolution of cystoid macular edema at 4 months. CONCLUSION: Bromfenac may be a useful addition to the treatment of UME.


How to cite this article:
Saade JS, Istambouli R, AbdulAal M, Antonios R, Hamam RN. Bromfenac 0.09% for the treatment of macular edema secondary to noninfectious uveitis.Middle East Afr J Ophthalmol 2021;28:98-103


How to cite this URL:
Saade JS, Istambouli R, AbdulAal M, Antonios R, Hamam RN. Bromfenac 0.09% for the treatment of macular edema secondary to noninfectious uveitis. Middle East Afr J Ophthalmol [serial online] 2021 [cited 2022 May 23 ];28:98-103
Available from: http://www.meajo.org/article.asp?issn=0974-9233;year=2021;volume=28;issue=2;spage=98;epage=103;aulast=Saade;type=0